)
Indian generic drugmaker Ranbaxy Laboratories reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.
The company's net loss in the October-December period was at Rs 1,030 crore ($167.8 million), compared with a loss of Rs 160 crore posted in the same quarter last year, it said in a statement to the exchanges on Wednesday.
Ranbaxy, which is being acquired by larger local rival Sun Pharmaceutical Industries Ltd for $3.2 billion, has been hit by a series of regulatory sanctions in the past year due to poor production practices at its India-based plants.
